Mendus to participate in several investor and industry conferences in November and to host investor webcast and lunch on November 9
Press release
Stockholm, Sweden, October 26, 2023
Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming investor and industry conferences:
38th Society for the Immunotherapy of Cancer meeting (SITC 2023)
San Diego, USA, November 1-5, 2023
Publication of updated clinical data from the ongoing Phase 1 ALISON study with the company's lead development program vididencel. Full abstracts are expected to be published online on October 31, 2023.
https://www.sitcancer.org/2023/home
BIO-Europe 2023 – 29th Annual International Partnering Conference
Munich, Germany, November 6-8, 2023
Mendus CEO Erik Manting will participate.
https://informaconnect.com/bioeurope/
Inv€$tival Showcase
London, United Kingdom, November 13, 2023
Mendus CEO Erik Manting and CFO Lotta Ferm will participate and present the company.
https://www.lsxleaders.com/investival-showcase
Jefferies London Healthcare Conference
London, United Kingdom, November 14-16, 2023
Mendus CEO Erik Manting will participate.
https://www.jefferies.com/OurFirm/ConferenceList/Investment-Conferences/159
Joint Belgian-Dutch Immunology Meeting 2023
Antwerp, Belgium, November 21-22, 2023
Updated immunomonitoring data from the Advance II study will be presented.
https://www.nvvi-dsi.nl/events2/joint-belgian-dutch-immunology-meeting-2023
Redeye Life Science Day
Stockholm, Sweden, November 23
Mendus CEO Erik Manting will participate and present the company.
https://www.redeye.se/events/915984/redeye-life-science-day-2023
Investor call and in-person event on November 9
Mendus also announces two investor events following the publication of its Q3 report on November 9, 2023:
Investor update - webcast
November 9, 2023 at 10:00am CET
Mendus will publish its interim report for the third quarter 2023 on Thursday, November 9 at 8.00 am CET. The company will hold a conference call and webcast presentation on the same day at 10.00am CET, to provide an update on the latest developments and the outlook for the remainder of the year.
The webcast will be webcasted live via the link: https://ir.financialhearings.com/mendus-q3-2023
Investor lunch - in person event
Mendus Head Office, Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, November 9 at 12.00-13.00 CET
Mendus invites you to an investor lunch and company update with Mendus management and Ted Fjällman, CEO of Flerie and board member of NorthX Biologics. The number of places is limited. Please register per email via ir@mendus.com
FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting, CEO
E-mail: ir@mendus.com
ABOUT MENDUS AB (PUBL)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Changes in the number of own shares held by Aktia Bank Plc28.11.2023 13:00:00 CET | Press release
Aktia Bank Plc Stock Exchange Release 28 November 2023 at 2.00 p.m. Changes in the number of own shares held by Aktia Bank Plc Aktia Bank Plc has today, based on a decision made by the company's Board of Directors, divested a total of 808 own shares held by the company to four persons as a deferred payment based on the company’s remuneration programs. The divestment of own shares is based on the authorisation by the Annual General Meeting of Shareholders held on 5 April 2023. After the above-mentioned divestments, a total of 159,538 shares remain in the company’s possession. Aktia Bank Plc Further information: Mia Smeds, Communications director, +358 44 546 0379, mia.smeds(at)aktia.fi Distribution: Nasdaq Helsinki Ltd Mass media www.aktia.com Aktia is a Finnish asset manager, bank and life insurer that has been creating wealth and wellbeing from one generation to the next for 200 years. We serve our customers in digital channels everywhere and face-to-face in our offices in the Helsink
Ändringar i antalet egna aktier i Aktia Bank Abp:s besittning28.11.2023 13:00:00 CET | Pressemelding
Aktia Bank Abp Börsmeddelande 28.11.2023 kl. 14.00 Ändringar i antalet egna aktier i Aktia Bank Abp:s besittning Aktia Bank Abp har idag med stöd av ett beslut av bolagets styrelse överlåtit totalt 808 Aktia-aktier i bolagets besittning till fyra personer som betalning av uppskjutna ersättningar enligt bolagets belöningssystem. Överlåtelsen av aktier är baserad på bemyndiganden av den ordinarie bolagsstämman 5.4.2023. Efter ovan nämnda överlåtelser har bolaget sammanlagt 159 538 aktier i sin besittning. Aktia Bank Abp Mera information: Mia Smeds, kommunikationsdirektör, tfn 044 546 0379, mia.smeds(at)aktia.fi Distribution: Nasdaq Helsinki Oy Massmedier www.aktia.com Aktia är en finländsk kapitalförvaltare, bank och livförsäkrare som har skapat välstånd och välfärd generation efter generation redan under 200 års tid. Vi tillhandahåller våra kunder digitala tjänster i ett flertal kanaler och ger personlig service på våra verksamhetsställen i huvudstadsregionen samt i Åbo-, Tammerfors-, V
Karolinska Developments portföljbolag Umecrine Cognition presenterar positiv effekt med golexanolon i en preklinisk modell av kolestas28.11.2023 12:44:51 CET | Pressemelding
STOCKHOLM, SVERIGE 28 november 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har presenterat positiva resultat från en studie med bolagets läkemedelskandidat golexanolone i en preklinisk modell av PBC-relaterad symtomologi och neuroinflammation. Resultaten indikerar en normaliserande effekt på kognitiva symtom såsom trötthet, motoriska störningar, neuroinflammation och neurala signaler. Resultaten publiceras i novemberutgåvan av den internationellt välrenommerade tidskriften Liver International. Resultaten från den prekliniska studien, som utfördes i en validerad och välkänd sjukdomsmodell av kolestas, visar att golexanolon förbättrar symtom som vanligtvis ses vid PBC. Studien visar en tydlig minskning av central trötthet, signifikanta förbättringar av korttidsminnet och normaliserande motoriska funktioner efter en 4-5 veckors lång behandling med golexanolon. ”Trötthet är högst prioriterat för symtomlindring för PBC-patienter e
Karolinska Development’s portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis28.11.2023 12:44:51 CET | Press release
STOCKHOLM, SWEDEN – November 28, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented positive results from a study of the company’s drug candidate golexanolone in a preclinical model of PBC-like symptomology and neuroinflammation. The results indicate a normalizing effect on cognitive symptoms, such as fatigue, motor impairments, neuroinflammation, and neural signaling. The results are published in the November issue of the internationally renowned journal Liver International. The results from the preclinical study, which was performed in a validated and well-known disease model of cholestasis, show that golexanolone improves symptoms generally seen in PBC. The study shows a clear reduction in central fatigue, marked improvements in short-term memory, and normalized motoric functions following a 4–5-week treatment regimen with golexanolone. “Fatigue is the highest priority of symptom relief for PBC patient
Vardagen fångad i blixtbelysning28.11.2023 12:19:36 CET | Pressemelding
Uppsala, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Lars Tunbjörk 2 dec - 28 jan 2024 Bror Hjorths Hus, Uppsala Lars Tunbjörks fotografier visas i Bror Hjorths Hus Årets sista utställning i Bror Hjorths Hus visar verk ut tre serier av den svenska fotografen Lars Tunbjörk (1956–2015). Den invigs lördag 2 december och pågår till 28 januari 2024. Pressvisning: lämpligast torsdag 30 november kl 10-14 (se mer nedan) Lars Tunbjörk skapade en helt egen fotografisk stil. Den genomsyrade alla hans bilder, oavsett om det rörde sig om foton av hemstaden Borås, det svenska landskapet och dess olika årstider, kontorsmiljöer eller modeller i Paris. Med en säregen blick, tålamod och passion dokumenterade han vardagen i skarp blixtbelysning. Lars Tunbjörks började som pressfotograf och 1982 fick han utmärkelsen Årets fotograf. Det stora genombrottet kom drygt tio år senare med fotoboken Landet utom sig – en både roande och oroande dokumentation av svensk vardag runt decennieskiftet 1990. Ett urval av dessa fot